Switzerland Archives

News and Trends 14 Nov 2014

A Way to Control Genes within Human Brain?

Researchers at the Department of Biosystems in Basel have developed a novel gene regulation method that enables thought-specific brainwaves to control the conversion of genes into proteins, so the genes expression. It opens new ways to control gene expression within your brain and could lead to brain surgeries. In this new study, bioengineers placed implants inside […]

November 14, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 6 Nov 2014

The First Patient Receives an Implant Pump System to manage Pleural Effusions

For the first time, a pleurapump system designed to manage chronic pleural effusions was implanted in a patient in Marseille (France). This is an innovative device from Sequana Medical AG, a private Swiss medical device company. Chronic pleural effusions is recurrence of excess fluid which collects around the lungs. The most common causes of it are congestive heart […]

November 6, 2014 - 2 minutesmins - By Julie Lellouche

CSL pays 275m to acquire Novartis flu vaccines manufacturing sites strict xxl

News and Trends 31 Oct 2014

Novartis steps down completely from Vaccines’ Business

Novartis divests its influenza vaccines business to CSL Limited, an Australian company, for an agreed price of 219 million euros, completing the last deal with GSK a few months ago. This is a strategic move of Novartis; they plan to focus on the pharmaceutical business, ophthalmology (Alcon) and generics (Sandoz). Last year, influenza vaccine business reached a turnover of 1 […]

October 31, 2014 - 2 minutesmins - By Julie Lellouche

Sophia Genetics is the first European bioinformatic company allowed to analyze clinical genetic data

News and Trends 17 Sep 2014

Sophia Genetics: the first European bioinformatic company allowed to analyze clinical genetic data

Sophia Genetics has become the first European company to obtain a CE-IVD mark allowing the use of their bioinformatic algorithms to analyse clinical data obtained through Next Generation Sequencing. This certification is an important step in making these in the standard use of routine genetic testing and clinical diagnosis. It brings Sophia Genetics’ world-leading Data Driven Medicine platform to […]

September 17, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 4 Sep 2014

Art Levinson says goodbye to Roche and will focus on Calico’s development

Roche announced today that Arthur D. Levinson has resigned from the Board of Directors, effective immediately. Arthur D. Levinson made this decision so as to avoid any conflict of interest given his role as Chief Executive Officer at Calico. “I would like to thank Art for his many important contributions, both as a member […]

September 4, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 25 Aug 2014

The new strategy of Novartis to acquire Gamida Cell

The deal for the sale of Gamida Cell to Novartis is back on. Instead of a huge exit in hundreds of millions of dollars, this time the deal is in multiple stages, starting with an injection of several dozen millions of dollars into the company. Gamida Cell, developer of a stem-cell treatment for blood cancer, announced today that it […]

August 25, 2014 - 2 minutesmins - By Joachim Eeckhout

News and Trends 21 Aug 2014

Stemedica International succeed in a pre-clinical trial to treat Alzheimer’s disease with stem cells

Stemedica International, a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. The results demonstrated a greater than 30% decrease in amyloid beta (Abeta) plaques in […]

August 21, 2014 - 2 minutesmins - By Joachim Eeckhout

News and Trends 15 Aug 2014

Active Biotech and Teva together in a Phase II clinical trial against Huntington’s disease

Active Biotech announced today that its partner Teva Pharmaceutical will initiate a phase II clinical trial to evaluate the efficacy and safety of oral laquinimod for the treatment of Huntington’s disease. Laquinimod is a once-daily oral, investigational, CNS-active immunomodulator with a novel mechanism of action being developed primarily for the treatment of relapsing-remitting multiple sclerosis […]

August 15, 2014 - 1 minutemin - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us